However, most obesity specialists agree that obesity is a multifaceted disease that can involve genetic predisposition and dysfunction of certain hormones, including ghrelin (a hunger hormone) and leptin (a satiety hormone)
Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies
INTRODUCCIN El sistema gastrointestinal contiene un conjunto de clulas entero-endocrinas especializadas en el epitelio gstrico e intestinal, las cuales secretan neuropptidos y hormonas que se encargan de la regulacin del apetito, la captacin de nutrientes, la motilidad intestinal y el metabolismo
1997, 25, 335358 (2) Berk M
In a study of more than 3,000 adults with obesity, the highest dose of orforglipron resulted in an average weight loss of 27.3 pounds over 72 weeks, with a safety profile consistent with injectable GLP-1s
The article flags rapid weight regain, unmanageable hunger, or metabolic instability as signals that continued medical support may be warranted
